Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.

Howes OD, Rogdaki M, Findon JL, Wichers RH, Charman T, King BH, Loth E, McAlonan GM, McCracken JT, Parr JR, Povey C, Santosh P, Wallace S, Simonoff E, Murphy DG.

J Psychopharmacol. 2018 Jan;32(1):3-29. doi: 10.1177/0269881117741766. Epub 2017 Dec 14.

2.

An Overview of Autism Spectrum Disorder, Heterogeneity and Treatment Options.

Masi A, DeMayo MM, Glozier N, Guastella AJ.

Neurosci Bull. 2017 Apr;33(2):183-193. doi: 10.1007/s12264-017-0100-y. Epub 2017 Feb 17. Review.

3.

d-Cycloserine enhances durability of social skills training in autism spectrum disorder.

Wink LK, Minshawi NF, Shaffer RC, Plawecki MH, Posey DJ, Horn PS, Adams R, Pedapati EV, Schaefer TL, McDougle CJ, Swiezy NB, Erickson CA.

Mol Autism. 2017 Jan 25;8:2. doi: 10.1186/s13229-017-0116-1. eCollection 2017.

4.

Treatment of Autism Spectrum Disorder in Children and Adolescents.

DeFilippis M, Wagner KD.

Psychopharmacol Bull. 2016 Aug 15;46(2):18-41.

5.

Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes.

Frye RE, Rossignol DA.

Clin Med Insights Pediatr. 2016 Jun 15;10:43-56. doi: 10.4137/CMPed.S38337. eCollection 2016. Review.

6.

Transcranial magnetic stimulation in autism spectrum disorder: Challenges, promise, and roadmap for future research.

Oberman LM, Enticott PG, Casanova MF, Rotenberg A, Pascual-Leone A, McCracken JT; TMS in ASD Consensus Group.

Autism Res. 2016 Feb;9(2):184-203. doi: 10.1002/aur.1567. Epub 2015 Nov 4. Review.

7.

Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis.

Masi A, Lampit A, Glozier N, Hickie IB, Guastella AJ.

Transl Psychiatry. 2015 Sep 22;5:e640. doi: 10.1038/tp.2015.143.

8.

Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date.

Fung LK, Hardan AY.

CNS Drugs. 2015 Jun;29(6):453-63. doi: 10.1007/s40263-015-0252-0. Review.

9.

Synaptic proteins and receptors defects in autism spectrum disorders.

Chen J, Yu S, Fu Y, Li X.

Front Cell Neurosci. 2014 Sep 11;8:276. doi: 10.3389/fncel.2014.00276. eCollection 2014. Review.

10.

Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children.

Kirino E.

Clin Med Insights Pediatr. 2014 May 25;8:17-30. doi: 10.4137/CMPed.S8304. eCollection 2014. Review.

11.

The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment.

Rojas DC.

J Neural Transm (Vienna). 2014 Aug;121(8):891-905. doi: 10.1007/s00702-014-1216-0. Epub 2014 Apr 22. Review.

12.

ASD: Psychopharmacologic Treatments and Neurophysiologic Underpinnings.

Kodish I, Rockhill CM, Webb SJ.

Curr Top Behav Neurosci. 2014;21:257-75. doi: 10.1007/7854_2014_298.

13.

The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome.

Uzunova G, Hollander E, Shepherd J.

Curr Neuropharmacol. 2014 Jan;12(1):71-98. doi: 10.2174/1570159X113116660046.

14.

Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial.

King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L, Hollander E, Bregman JD, Anagnostou E, Robinson F, Sullivan L, Hirtz D.

JAMA Pediatr. 2013 Nov;167(11):1045-52. doi: 10.1001/jamapediatrics.2013.2698.

15.

Autism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses.

Won H, Mah W, Kim E.

Front Mol Neurosci. 2013 Aug 5;6:19. doi: 10.3389/fnmol.2013.00019. eCollection 2013.

16.

Rats selectively bred for low levels of play-induced 50 kHz vocalizations as a model for autism spectrum disorders: a role for NMDA receptors.

Burgdorf J, Moskal JR, Brudzynski SM, Panksepp J.

Behav Brain Res. 2013 Aug 15;251:18-24. doi: 10.1016/j.bbr.2013.04.022. Epub 2013 Apr 23. Review.

17.

Pharmacotherapy for the core symptoms in autistic disorder: current status of the research.

Farmer C, Thurm A, Grant P.

Drugs. 2013 Mar;73(4):303-14. doi: 10.1007/s40265-013-0021-7. Review.

18.

Amantadine: a review of use in child and adolescent psychiatry.

Hosenbocus S, Chahal R.

J Can Acad Child Adolesc Psychiatry. 2013 Feb;22(1):55-60.

19.

Assessment and treatment in autism spectrum disorders: a focus on genetics and psychiatry.

Butler MG, Youngs EL, Roberts JL, Hellings JA.

Autism Res Treat. 2012;2012:242537. doi: 10.1155/2012/242537. Epub 2012 May 31.

20.

Review of the pharmacotherapy of irritability of autism.

Elbe D, Lalani Z.

J Can Acad Child Adolesc Psychiatry. 2012 May;21(2):130-46.

Supplemental Content

Support Center